Rydell Niclas, Ekoff Helena, Hellström Per M, Movérare Robert
Thermo Fisher Scientific, SE-75137 Uppsala, Sweden.
Department of Medical Sciences, Gastroenterology and Hepatology, Uppsala University, SE-75185 Uppsala, Sweden.
J Clin Med. 2022 Mar 28;11(7):1881. doi: 10.3390/jcm11071881.
IgG anti-integrin αvβ6 autoantibodies (IgG anti-αvβ6) have been described as highly sensitive and specific markers of ulcerative colitis (UC) in the sera of Japanese inflammatory bowel disease (IBD) patients. We aimed to evaluate the diagnostic performance of IgG anti-αvβ6 as a biomarker in Swedish patients with IBD or irritable bowel syndrome (IBS). The study included adult UC (n = 59), Crohn’s disease (CD, n = 38), and IBS patients (n = 100). Partial Mayo score and Harvey−Bradshaw index were used to assess disease severity for UC and CD, respectively. Serum levels of IgG anti-αvβ6, reported as absorbance units (AU), were measured using an in-house ELISA where the 95th percentile of 76 healthy controls defined positivity. Faecal calprotectin (fCP) was measured using a commercial assay. The majority of the IBD patients were on medical treatment, and many were in remission (UC: 40.7%; CD: 47.4%). Seventy-one percent of the UC patients, 74.2% of CD patients, and 23.1% of the IBS patients had fCP test results >50 mg/kg. The UC group had significantly higher IgG anti-αvβ6 levels (median: 1.76 AU) than the CD and IBS groups (0.34 and 0.31 AU, both p < 0.0001). The diagnostic sensitivity of IgG anti-αvβ6 in UC was 76.3%, and the specificities were 79.0% (vs. CD) and 96.0% (vs. IBS). The IgG anti-αvβ6 levels related to disease severity of the UC patients (p < 0.01−0.05). Our study shows that IgG anti-αvβ6 is associated with UC in Swedish IBD patients and that the levels of the autoantibodies reflect disease severity. IgG anti-αvβ6 could be an attractive complement to fCP in the diagnostic work up of IBD patients.
在日本炎症性肠病（IBD）患者血清中，IgG抗整合素αvβ6自身抗体（IgG抗αvβ6）已被描述为溃疡性结肠炎（UC）高度敏感且特异的标志物。我们旨在评估IgG抗αvβ6作为生物标志物在瑞典IBD或肠易激综合征（IBS）患者中的诊断性能。该研究纳入了成年UC患者（n = 59）、克罗恩病（CD，n = 38）和IBS患者（n = 100）。分别采用部分梅奥评分和哈维-布拉德肖指数评估UC和CD的疾病严重程度。使用内部酶联免疫吸附测定（ELISA）法测量血清IgG抗αvβ6水平，以吸光度单位（AU）表示，其中76名健康对照者的第95百分位数定义为阳性。使用商业检测法测量粪便钙卫蛋白（fCP）。大多数IBD患者正在接受治疗，许多患者处于缓解期（UC：40.7%；CD：47.4%）。71%的UC患者、74.2%的CD患者和23.1%的IBS患者fCP检测结果>50 mg/kg。UC组的IgG抗αvβ6水平（中位数：1.76 AU）显著高于CD组和IBS组（分别为0.34和0.31 AU，p均<0.0001）。IgG抗αvβ6在UC中的诊断敏感性为76.3%，特异性分别为79.0%（相对于CD）和96.0%（相对于IBS）。IgG抗αvβ6水平与UC患者的疾病严重程度相关（p < 0.01 - 0.05）。我们的研究表明，在瑞典IBD患者中，IgG抗αvβ6与UC相关，且自身抗体水平反映疾病严重程度。在IBD患者的诊断检查中，IgG抗αvβ6可能是fCP的一个有吸引力的补充指标。
